head and neck cancer
Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments
March 1, 2021Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant
German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …
First-line Keytruda shows better overall survival in head & neck cancer
October 23, 2018Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …
Opdivo to go before EU, US regulators in head and neck cancer
July 19, 2016Manufacturing and Production, Research and Development EMA, EU, FDA, US, head and neck cancer, opdivo
Bristol-Myers Squibb has announced that its lead oncology drug, Opdivo (nivolumab), is set to go before regulators in the US …
Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials
April 19, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous
Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
Amgen’s Vectibix fails late stage trial
August 12, 2010Research and Development, Sales and Marketing Amgen, Vectibix, head and neck cancer
Amgen’s potential head and neck cancer treatment Vectibix has failed to meet its primary endpoint of improving overall survival in …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
